

Medicines for COVID-19

Section

Medicines for COVID-19
Refer to WHO living guidelines

Indications

COVID-19

Abacavir

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (as sulfate)

Indications

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified

Abacavir + lamivudine

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

Indications

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified

Abacavir + lamivudine + lopinavir + ritonavir

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral
granules

Indications

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified

Aciclovir

Section

Antiherpes medicines
Parenteral > General injections > IV: 250 mg in vial powder for injection
(as sodium salt)
Oral > Liquid: 200 mg per 5 mL
Oral > Solid: 200 mg tablet

Indications

Zoster

Varicella

Herpes simplex infections

Albendazole

Section

Intestinal anthelmintics

Oral > Solid > tablet: 400 mg (chewable, scored)

Cysticidal medicines

Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)

Antifilarials

Oral > Solid > tablet: 400 mg (chewable, scored)

Indications

Echinococcosis

Enterobiasis

Trichuriasis

Hookworm diseases

Cysticercosis

Ascariasis

Other specified echinococcosis

Cysticercosis of central nervous system

Lymphatic filariasis

Amikacin

Section

Antituberculosis medicines

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Access group antibiotics

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

First choice

Neutropenia (high-risk)

co-prescribed with cefotaxime

Inflammatory and other diseases of prostate (severe)

co-prescribed with cefotaxime

Acute pyelonephritis (severe)

co-prescribed with ceftriaxone

Inflammatory and other diseases of prostate (severe)

co-prescribed with ceftriaxone

Acute pyelonephritis (severe)

Second choice

co-prescribed with cloxacillin

Sepsis without septic shock

Amodiaquine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Amodiaquine + sulfadoxine + pyrimethamine

Section

Antimalarial medicines > For chemoprevention

Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package

Indications

Malaria

Amoxicillin

Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid

Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection

Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Acute malnutrition in infants, children or adolescents (uncomplicated) [children]

Acute malnutrition in infants, children or adolescents (complicated) [children]

Acute pharyngitis

Chronic obstructive pulmonary disease with acute exacerbation

Periapical abscess without sinus

Acute otitis media

Acute sinusitis

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with gentamicin

Sepsis without septic shock

Second choice

Bacterial meningitis

Other indications

Infectious cystitis

Bacterial infection of unspecified site

Amoxicillin + clavulanic acid

Section

Access group antibiotics

Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection

Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Antituberculosis medicines

Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

First choice

Peritoneal abscess (mild-moderate)

Neutropenia (low-risk)

Other specified pneumonia (Hospital-acquired pneumonia)

Infectious cystitis

Chronic obstructive pulmonary disease with acute exacerbation

Peritonitis (mild-moderate)

Acute sinusitis

Bacterial cellulitis, erysipelas or lymphangitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choice

Osteomyelitis or osteitis

Acute otitis media

Other specified prophylactic measures

Bacterial infection of joint

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

co-prescribed with clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

Other indications

Bacterial infection of unspecified site

Multi-drug resistant Mycobacterium tuberculosis

Amphotericin B

Section

Antifungal medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Antileishmaniasis medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Indications

Blastomycosis

Cryptococcosis

Candidosis

Coccidioidomycosis

Histoplasmosis

Sporotrichosis

Aspergillosis

Visceral leishmaniasis

Ampicillin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension

Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

co-prescribed with gentamicin

Peritoneal abscess (severe)

co-prescribed with gentamicin

Sepsis without septic shock

co-prescribed with gentamicin

Peritoneal abscess (mild-moderate)

co-prescribed with gentamicin

Peritonitis (severe)

co-prescribed with gentamicin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with gentamicin

Peritonitis (mild-moderate)

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Anidulafungin

Section

Antifungal medicines

Indications

Therapeutic equivalent to micafungin for

Systemic or invasive candidosis

Ansuvimab

Section

Medicines for Ebola virus disease

Parenteral > General injections > IV: 400 mg powder for injection

Indications

Ebola virus disease

Artemether

Section

Antimalarial medicines > For curative treatment

Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artemether + lumefantrine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate

Section

Antimalarial medicines > For curative treatment

Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution

Oral > Solid: 50 mg tablet

Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate + amodiaquine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet

Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

Artesunate + mefloquine

Section

Antimalarial medicines > For curative treatment
Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Artesunate + pyronaridine tetraphosphate

Section

Antimalarial medicines > For curative treatment
Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Atazanavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atazanavir + ritonavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atoltivimab + maftivimab + odesivimab

Section

Medicines for Ebola virus disease
Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

Indications

Ebola virus disease

Azithromycin

Section

Watch group antibiotics

Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

Chlamydia trachomatis

Typhoid fever

Yaws

Paratyphoid fever

Cholera

Cholera [children]

Trachoma

co-prescribed with ceftriaxone

Gonococcal infection

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with cefixime

Gonococcal infection

Aztreonam

Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified bacterial diseases

Bedaquiline

Section

Antituberculosis medicines

Oral > Solid: 100 mg tablet; 20 mg tablet

Indications

Multi-drug resistant Mycobacterium tuberculosis

Benzathine benzylpenicillin

Section

Access group antibiotics

Parenteral > General injections > IM: 1.2 million IU in vial (\approx 900 mg) powder for injection; 2.4 million IU in vial (\approx 1.8 g) powder for injection

Indications

First choice

Syphilis

Congenital syphilis [children]

Other indications

Bacterial infection of unspecified site

Benznidazole

Section

American trypanosomiasis

Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg

Indications

Chagas disease

Benzylpenicillin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Indications

First choice

Congenital syphilis [children]

Syphilis

co-prescribed with gentamicin

Sepsis without septic shock

co-prescribed with gentamicin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Capreomycin

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant Mycobacterium tuberculosis

Caspofungin

Section

Antifungal medicines

Indications

Therapeutic equivalent to micafungin for

Systemic or invasive candidosis

Cefalexin

Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid: 250 mg (as monohydrate)

Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)

Oral > Solid > dispersible tablet: 125 mg; 250 mg

Indications

First choice

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Acute pharyngitis

Chronic obstructive pulmonary disease with acute exacerbation

Other indications

Bacterial infection of unspecified site

Cefazolin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

First choice

Other specified prophylactic measures

co-prescribed with metronidazole

Other specified prophylactic measures

Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

Other indications

Surgical site infection

Cefepime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

Other specified bacterial diseases

Cefiderocol

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Cefixime

Section

Watch group antibiotics

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with [azithromycin](#)

Gonococcal infection

Cefotaxime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial meningitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with amikacin

Inflammatory and other diseases of prostate (severe)

co-prescribed with amikacin

Acute pyelonephritis (severe)

co-prescribed with clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with metronidazole

Peritonitis (severe)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

co-prescribed with metronidazole

Peritoneal abscess (severe)

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Sepsis without septic shock

Other indications

Bacterial infection of unspecified site

Ceftaroline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

Other specified bacterial diseases

Ceftazidime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

co-prescribed with [vancomycin](#)

[Endophthalmitis](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

Ceftazidime + avibactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

[Carbapenem resistant Enterobacterales](#)

Ceftolozane + tazobactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

Ceftriaxone

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Indications

First choice

[Typhoid fever](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

[Paratyphoid fever](#)

[Other specified pneumonia \(Hospital-acquired pneumonia\)](#)

[Bacterial meningitis](#)

co-prescribed with [amikacin](#)

[Acute pyelonephritis \(severe\)](#)

co-prescribed with [amikacin](#)

[Inflammatory and other diseases of prostate \(severe\)](#)

co-prescribed with [azithromycin](#)

[Gonococcal infection](#)

co-prescribed with [clarithromycin](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

co-prescribed with metronidazole

Necrotising fasciitis

co-prescribed with metronidazole

Peritonitis (mild-moderate)

co-prescribed with metronidazole

Peritonitis (severe)

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Peritoneal abscess (severe)

co-prescribed with vancomycin

Endophthalmitis

Second choice

Bacterial infection of joint

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Sepsis without septic shock

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Other indications

Bacterial infection of unspecified site

Cefuroxime

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

Other specified prophylactic measures

Chloramphenicol

Section

Access group antibiotics

Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)

Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection

Oral > Liquid: 150 mg per 5 mL (as palmitate)

Oral > Solid: 250 mg capsule

Indications

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

Chloroquine

Section

Antimalarial medicines > For chemoprevention

Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)

Oral > Solid: 150 mg tablet (as phosphate or sulfate)

Antimalarial medicines > For curative treatment

Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)

Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)

Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Malaria due to *Plasmodium ovale*

Malaria due to *Plasmodium malariae*

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Ciprofloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hyclate)

Oral > Liquid: 250 mg per 5 mL (anhydrous)

Oral > Solid: 250 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

First choice

Neutropenia (low-risk)

Inflammatory and other diseases of prostate (mild to moderate)

Typhoid fever

Paratyphoid fever

Infectious gastroenteritis or colitis without specification of infectious agent

Acute pyelonephritis (mild to moderate)

Second choice

Cholera

Cholera [children]

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

Other indications

Bacterial infection of unspecified site

Clarithromycin

Section

Watch group antibiotics

Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Oral > Solid > dosage form: 500 mg; 250 mg

Oral > Solid > dosage form: 500 mg

Indications

First choice

co-prescribed with cefotaxime

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with ceftriaxone

Bacterial pneumonia (Community-acquired pneumonia - severe)

Second choice

Acute pharyngitis

co-prescribed with amoxicillin + clavulanic acid

Bacterial pneumonia (Community-acquired pneumonia - severe)

Other indications

Helicobacter pylori associated gastric ulcer

Clindamycin

Section

Access group antibiotics

Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride) capsule

Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection

Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)

Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride)

Indications

First choice

co-prescribed with [piperacillin + tazobactam](#)

[Necrotising fasciitis](#)

Second choice

[Osteomyelitis or osteitis](#)

[Bacterial infection of joint](#)

Other indications

[Bacterial infection of unspecified site](#)

Clofazimine

Section

Antituberculosis medicines

Oral > Solid: 100 mg; 50 mg

Antileprosy medicines

Oral > Solid: 100 mg; 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

[Leprosy](#)

Clotrimazole

Section

Antifungal medicines

Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet

Indications

[Vulvovaginal candidosis](#)

Cloxacillin

Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid

Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection

Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

Indications

First choice

Bacterial infection of joint

Osteomyelitis or osteitis

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

co-prescribed with amikacin

Sepsis without septic shock

Other indications

Bacterial infection of unspecified site

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Colistin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Cycloserine

Section

Antituberculosis medicines
Oral > Solid: 250 mg; 125 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Daclatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride)

Indications

Chronic hepatitis C

Daclatasvir + sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid > tablet: 60 mg + 400 mg

Indications

Chronic hepatitis C

Dapsone

Section

Antileprosy medicines
Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

Indications

Leprosy

Daptomycin

Section

Reserve group antibiotics
Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

Other specified bacterial diseases

Darunavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dasabuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 250 mg tablet

Indications

Chronic hepatitis C

Delafloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 300 mg lyophilized powder for injection

Oral > Solid: 450 mg

Indications

Methicillin resistant *Staphylococcus aureus*

Delamanid

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 25 mg

Oral > Solid > tablet: 50 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Didanosine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution

Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Diethylcarbamazine

Section

Antifilarials

Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)

Indications

Lymphatic filariasis

Dihydroartemisinin + piperazine phosphate

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Diloxanide

Section

Antiamoebic and anti giardiasis medicines

Oral > Solid: 500 mg (furoate)

Indications

Amoebiasis

Dolutegravir

Section

Antiretrovirals > Integrase inhibitors

Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dolutegravir + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Doxycycline

Section

Access group antibiotics

Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)

Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)

Oral > Solid > dispersible tablet: 100 mg (as monohydrate)

Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)

Oral > Solid > dosage form: 100 mg (as hyclate)

Antimalarial medicines > For curative treatment

Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

Antimalarial medicines > For chemoprevention

Oral > Solid: 100 mg (hydrochloride or hyclate)

Indications

First choice

Chlamydia trachomatis

Cholera

Second choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Chronic obstructive pulmonary disease with acute exacerbation

Cholera [children]

Other indications

Bacterial infection of unspecified site

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium falciparum

Efavirenz

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
Oral > Solid: 600 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Eflornithine

Section

Medicines for the treatment of 2nd stage African trypanosomiasis
Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)

Indications

African trypanosomiasis

Elbasvir + grazoprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 50 mg + 100 mg

Indications

Chronic hepatitis C

Emtricitabine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Liquid: 10 mg per mL
Oral > Solid: 200 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 200 mg + 25 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Emtricitabine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Entecavir

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Liquid: 0.05 mg per mL
Oral > Solid: 0.5 mg; 1 mg

Indications

Chronic hepatitis B

Eravacycline

Section

Reserve group antibiotics
Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

Carbapenem resistant Enterobacterales

Erythromycin

Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)

Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)

Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

Second choice

Therapeutic equivalent to [clarithromycin](#) for

Acute pharyngitis

Other indications

Bacterial infection of unspecified site

Ethambutol

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

Other specified tuberculosis

Tuberculosis

Ethambutol + isoniazid

Section

Antituberculosis medicines

Oral > Solid: 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + rifampicin

Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

Tuberculosis

Ethionamide

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 125 mg

Oral > Solid > tablet: 250 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Tuberculous meningitis

Fexinidazole

Section

Medicines for the treatment of 1st stage African trypanosomiasis

Oral > Solid: 600 mg

Medicines for the treatment of 2nd stage African trypanosomiasis

Oral > Solid: 600 mg

Indications

African trypanosomiasis

African trypanosomiasis

Fifth generation cephalosporins

Section

Reserve group antibiotics

Indications

Other specified bacterial diseases

Flomoxef

Section

Watch group antibiotics

Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified other antibiotic resistant Enterobacterales

Fluconazole

Section

Antifungal medicines

Parenteral > General injections > IV: 2 mg per mL in vial

Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid

Oral > Solid > capsule: 50 mg

Indications

Cryptococcosis

Candidosis

Flucytosine

Section

Antifungal medicines

Parenteral > General injections > IV: 2.5 g per 250 mL infusion

Oral > Solid: 250 mg capsule

Indications

Cryptococcosis

Fosfomycin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section

Watch group antibiotics

.

Indications

Other specified bacterial diseases

Gatifloxacin

Section

Antituberculosis medicines

Oral > Solid: 200 mg; 400 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Gentamicin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

Neonatal meningitis

co-prescribed with amoxicillin

Sepsis without septic shock

co-prescribed with amoxicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Sepsis without septic shock

co-prescribed with ampicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with ampicillin

Peritoneal abscess (severe)

co-prescribed with ampicillin

Peritonitis (mild-moderate)

co-prescribed with ampicillin

Peritonitis (severe)

co-prescribed with ampicillin

Peritoneal abscess (mild-moderate)

co-prescribed with benzylpenicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with benzylpenicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with benzylpenicillin

Sepsis without septic shock

Second choice

Other specified prophylactic measures

Gonococcal infection

Other indications

Bacterial infection of unspecified site

Glecaprevir + pibrentasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 50 mg + 20 mg granules

Oral > Solid > tablet: 100 mg + 40 mg

Indications

Chronic hepatitis C

Griseofulvin

Section

Antifungal medicines

Oral > Liquid: 125 mg per 5 mL

Oral > Solid: 125 mg; 250 mg

Indications

Dermatophytosis

Hydroxychloroquine

Section

Antimalarial medicines > For chemoprevention

Indications

Therapeutic equivalent to chloroquine for

Malaria due to Plasmodium falciparum

Imipenem + cilastatin

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

Second choice

Therapeutic equivalent to meropenem for

Neutropenia (high-risk)

Therapeutic equivalent to meropenem for

Peritoneal abscess (severe)

Therapeutic equivalent to meropenem for

Peritonitis (severe)

Other indications

Pseudomonas aeruginosa resistant to other antibiotic

Antibiotic resistant Acinetobacter baumannii

Therapeutic equivalent to meropenem for

Multi-drug resistant Mycobacterium tuberculosis

Antituberculosis medicines

Imipenem + cilastatin + relebactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection

Indications

Other specified other antibiotic resistant Enterobacterales

Carbapenem resistant Enterobacterales

Carbapenem-resistant Pseudomonas aeruginosa

Indinavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 400 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Isoniazid

Section

Antituberculosis medicines

Parenteral > General injections > IV: 100 mg per mL

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 100 mg; 300 mg

Indications

Other specified tuberculosis

Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg

Indications

Tuberculosis

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section

Medicines for prevention of HIV-related opportunistic infections

Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications

Other specified prophylactic measures

Isoniazid + rifampicin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 50 mg + 75 mg

Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

Indications

Tuberculosis

Isoniazid + rifapentine

Section

Antituberculosis medicines

Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

Latent tuberculosis

Itraconazole

Section

Antifungal medicines

Oral > Liquid: 10 mg per mL

Oral > Solid: 100 mg

Indications

Chronic pulmonary aspergillosis

Chromoblastomycosis

Histoplasmosis

Talaromycosis

Sporotrichosis

Paracoccidioidomycosis

Ivermectin

Section

Intestinal anthelmintics

Oral > Solid > tablet: 3 mg

Antifilarials

Oral > Solid > tablet: 3 mg

Medicines for ectoparasitic infections

Oral > Solid > tablet: 3 mg

Indications

Strongyloidiasis

Ascariasis

Trichuriasis

Hookworm diseases

Ancylostomiasis

Onchocerciasis

Lymphatic filariasis

Scabies

Kanamycin (injection)

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant Mycobacterium tuberculosis

Lamivudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 150 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + nevirapine + zidovudine

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Indications

Therapeutic equivalent to emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to emtricitabine + tenofovir for

Contact with or exposure to human immunodeficiency virus

Lamivudine + zidovudine

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ledipasvir + sofosbuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 90 mg + 400 mg tablet

Indications

Chronic hepatitis C

Levamisole

Section

Intestinal anthelmintics
Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)

Indications

Ascariasis

Levofloxacin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 250 mg; 500 mg; 750 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Linezolid

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 mg per mL in 300 mL bag

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 400 mg tablet; 600 mg tablet

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

Antituberculosis medicines

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

Indications

Other specified bacterial diseases

Methicillin resistant Staphylococcus aureus

Vancomycin resistant Staphylococcus aureus

Vancomycin resistant Enterococcus

Multi-drug resistant Mycobacterium tuberculosis

Lopinavir + ritonavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)

Oral > Solid > dosage form: 40 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Mebendazole

Section

Intestinal anthelmintics

Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Indications

Ascariasis

Enterobiasis

Trichuriasis

Hookworm diseases

Cysticidal medicines

Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Other specified echinococcosis

Mefloquine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 250 mg tablet (hydrochloride)

Antimalarial medicines > For chemoprevention

Oral > Solid: 250 mg tablet (hydrochloride)

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Malaria due to *Plasmodium falciparum*

Meglumine antimoniate

Section

Antileishmaniasis medicines

Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule

Indications

Visceral leishmaniasis

Cutaneous leishmaniasis

Mucocutaneous leishmaniasis

Melarsoprol

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)

Indications

African trypanosomiasis

Meropenem

Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Antituberculosis medicines

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choice

Neutropenia (high-risk)

Peritoneal abscess (severe)

Peritonitis (severe)

Neonatal meningitis

Multi-drug resistant *Mycobacterium tuberculosis*

Meropenem + vaborbactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Carbapenem resistant *Acinetobacter baumannii*

Metronidazole

Section

Access group antibiotics

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Oral > Solid: 200 to 500 mg tablet

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
Injection

Local > Rectal > Suppository: 500 mg; 1 g

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Antiamoebic and anti giardiasis medicines

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Parenteral > General injections > unspecified: 500 mg in 100 mL vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Indications

First choice

Intestinal infections due to *Clostridioides difficile*

Trichomoniasis

co-prescribed with cefazolin

Other specified prophylactic measures

co-prescribed with cefotaxime

Peritonitis (severe)

co-prescribed with cefotaxime

Peritonitis (mild-moderate)

co-prescribed with cefotaxime

Peritoneal abscess (mild-moderate)

co-prescribed with cefotaxime

Peritoneal abscess (severe)

co-prescribed with ceftriaxone

Necrotising fasciitis

co-prescribed with ceftriaxone

Peritonitis (severe)

co-prescribed with ceftriaxone

Peritoneal abscess (mild-moderate)

co-prescribed with ceftriaxone

Peritoneal abscess (severe)

co-prescribed with ceftriaxone

Peritonitis (mild-moderate)

Second choice

co-prescribed with ciprofloxacin

Peritonitis (mild-moderate)

co-prescribed with ciprofloxacin

Peritoneal abscess (mild-moderate)

Other indications

Bacterial infection of unspecified site

Amoebiasis

Micafungin

Section

Antifungal medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection

Indications

Systemic or invasive candidosis

Miltefosine

Section

Antileishmaniasis medicines

Oral > Solid: 10 mg; 50 mg

Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

Moxifloxacin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 400 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Tuberculosis

Nalidixic acid

Section

Anti-infective medicines

Oral > Solid: 250 mg; 500 mg

Indications

Shigella resistant to unspecified antibiotic

Nelfinavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 250 mg (as mesilate)

Oral > Other: 50 mg per g oral powder

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Nevirapine

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

Oral > Liquid: 50 mg per 5 mL

Oral > Solid > dispersible tablet: 50 mg

Oral > Solid > tablet: 200 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Niclosamide

Section

Intestinal anthelmintics

Oral > Solid: 500 mg tablet (chewable)

Indications

Hymenolepiasis

Diphyllobothriasis

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

Nifurtimox

Section

American trypanosomiasis

Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Medicines for the treatment of 2nd stage African trypanosomiasis

Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Indications

Chagas disease

African trypanosomiasis

Nitrofurantoin

Section

Access group antibiotics

Oral > Liquid: 25 mg per 5 mL oral liquid

Oral > Solid > dosage form: 100 mg; 50 mg

Indications

First choice

Infectious cystitis

Nystatin

Section

Antifungal medicines

Oral > Liquid: 100000 IU per mL

Local > Topical > Other: 100000 IU pessary

Oral > Solid > dosage form: 500000 IU

Oral > Solid > lozenge: 100000 IU

Indications

Candidosis

Ofloxacin

Section

Antituberculosis medicines

Oral > Solid: 200 mg; 400 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Omadacycline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 100 mg lyophilized powder for injection

Oral > Solid: 300 mg

Indications

Methicillin resistant *Staphylococcus aureus*

Ombitasvir + paritaprevir + ritonavir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications

Chronic hepatitis C

Oseltamivir

Section

Other antivirals

Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

Indications

Influenza due to identified seasonal influenza virus

Oxamniquine

Section

Antischistosomes and other antitrematode medicines

Oral > Liquid: 250 mg per 5 mL

Oral > Solid > capsule: 250 mg

Indications

Schistosomiasis due to *Schistosoma mansoni*

Oxazolindinones

Section

Reserve group antibiotics

.

Indications

Other specified bacterial diseases

P-aminosalicylate sodium

Section

Antituberculosis medicines

Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

P-aminosalicylic acid

Section

Antituberculosis medicines

Oral > Solid: 4 g granules in sachet

Indications

Multi-drug resistant Mycobacterium tuberculosis

Paromomycin

Section

Antileishmaniasis medicines

Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

Antiamoebic and anti giardiasis medicines

Oral > Liquid: 125 mg per 5 mL as sulfate

Oral > Solid: 250 mg as sulfate

Indications

Visceral leishmaniasis

Amoebiasis

Pegylated interferon alfa (2a)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

Chronic hepatitis C

Pegylated interferon alfa (2b)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

Chronic hepatitis C

Pentamidine

Section

Antileishmaniasis medicines

Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)

Medicines for the treatment of 1st stage African trypanosomiasis

Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection

Antipneumocystosis and antitoxoplasmosis medicines

Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)

Indications

Visceral leishmaniasis

African trypanosomiasis

Pneumocystosis

Phenoxyethylpenicillin

Section

Access group antibiotics

Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid

Oral > Solid: 250 mg (as potassium salt) tablet

Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

First choice

Acute pharyngitis

Periapical abscess without sinus

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Other indications

Bacterial infection of unspecified site

Piperacillin + tazobactam

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice

Peritoneal abscess (severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Neutropenia (high-risk)

Peritonitis (severe)

co-prescribed with clindamycin

Necrotising fasciitis

Plazomicin

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500 mg per 10 mL

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Polymyxin B (injection)

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Polymyxins

Section

Reserve group antibiotics

Indications

Other specified bacterial diseases

Potassium iodide

Section

Antifungal medicines

Local > Topical > Solution: Saturated solution

Indications

Sporotrichosis

Praziquantel

Section

Antischistosomes and other antitremitode medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Intestinal anthelmintics

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Cysticidal medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

Paragonimiasis

Clonorchiasis

Opisthorchiasis

Schistosomiasis

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

Hymenolepiasis

Diphyllobothriasis

Cysticercosis of central nervous system

Pretomanid

Section

Antituberculosis medicines

Oral > Solid > tablet: 200 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Primaquine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)

Indications

Malaria due to *Plasmodium ovale*

Malaria due to *Plasmodium vivax*

Procaine benzylpenicillin

Section

Access group antibiotics

Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

First choice

Congenital syphilis [children]

Second choice

Syphilis

Proguanil

Section

Antimalarial medicines > For chemoprevention

Oral > Solid: 100 mg tablet (hydrochloride)

Indications

Malaria due to Plasmodium falciparum

Protionamide

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to ethionamide for

Multi-drug resistant Mycobacterium tuberculosis

Pyrantel

Section

Intestinal anthelmintics

Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)

Indications

Ascariasis

Trichuriasis

Enterobiasis

Hookworm diseases

Pyrazinamide

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 400 mg; 500 mg

Indications

Tuberculosis

Pyrimethamine

Section

Antipneumocystosis and antitoxoplasmosis medicines

Oral > Solid: 25 mg

Indications

Toxoplasmosis

Quinine

Section

[Antimalarial medicines](#) > [For curative treatment](#)
Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)
Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)

Indications

Malaria due to *Plasmodium falciparum*

Raltegravir

Section

[Antiretrovirals](#) > [Integrase inhibitors](#)
Oral > Liquid: 100 mg granules for oral suspension
Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ravidasvir

Section

[Medicines for hepatitis C](#) > [Pangenotypic direct-acting antiviral combinations](#)
Oral > Solid > tablet: 200 mg

Indications

Chronic hepatitis C

Ribavirin

Section

[Other antivirals](#)
Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
Oral > Solid: 200 mg; 400 mg; 600 mg

[Medicines for hepatitis C](#) > [Other antivirals for hepatitis C](#)
Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

Viral haemorrhagic fever, not elsewhere classified

Chronic hepatitis C

Rifabutin

Section

[Antituberculosis medicines](#)
Oral > Solid: 150 mg

Indications

Tuberculosis

Rifampicin

Section

Antituberculosis medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

Parenteral > General injections > IV: 600 mg in vial powder for injection

Antileprosy medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

Indications

Tuberculosis

Other specified tuberculosis

Leprosy

Rifapentine

Section

Antituberculosis medicines

Oral > Solid > tablet: 150 mg; 300 mg

Indications

Tuberculosis

Latent tuberculosis

Ritonavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Saquinavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 200 mg; 500 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Simeprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 150 mg

Indications

Chronic hepatitis C

Sodium stibogluconate

Section

Antileishmaniasis medicines

Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

Sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid > tablet: 200 mg; 400 mg

Indications

Chronic hepatitis C

Sofosbuvir + velpatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg

Indications

Chronic hepatitis C

Spectinomycin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

Second choice

Gonococcal infection

Other indications

Bacterial infection of unspecified site

Stavudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 5 mg per 5 mL powder for oral solution

Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Streptomycin (injection)

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

Indications

Multi-drug resistant Mycobacterium tuberculosis

Sulfadiazine

Section

Antipneumocystosis and antitoxoplasmosis medicines

Oral > Solid: 500 mg

Anti-infective medicines

Oral > Solid: 500 mg

Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)

Indications

Toxoplasmosis

Bacterial infection of unspecified site

Sulfadimidine

Section

Anti-infective medicines

Oral > Liquid: 500 mg per 5 mL

Oral > Solid: 500 mg

Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)

Indications

Bacterial infection of unspecified site

Sulfadoxine + pyrimethamine

Section

Antimalarial medicines > For curative treatment

Oral > Solid: 500 mg + 25 mg tablet

Antimalarial medicines > For chemoprevention

Oral > Solid: 500 mg + 25 mg tablet

Oral > Solid: 250 mg + 12.5 mg tablet

Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

Malaria due to *Plasmodium falciparum*

Malaria

Sulfamethoxazole + trimethoprim

Section

Access group antibiotics

Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule

Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid

Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet

Oral > Solid > dispersible tablet: 100 mg + 20 mg

Antipneumocystosis and antitoxoplasmosis medicines

Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule

Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid

Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet

Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

First choice

Infectious cystitis

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

Other indications

Bacterial infection of unspecified site

Pneumocystosis

Suramin sodium

Section

Antifilarials

Parenteral > General injections > IV: 1 g in vial

Medicines for the treatment of 1st stage African trypanosomiasis

Parenteral > General injections > IV: 1 g in vial

Indications

Filariasis

African trypanosomiasis

Tedizolid

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to linezolid for

Methicillin resistant *Staphylococcus aureus*

Therapeutic equivalent to linezolid for

Vancomycin resistant *Staphylococcus aureus*

Therapeutic equivalent to linezolid for

Vancomycin resistant *Enterococcus*

Tenofovir alafenamide

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 25 mg

Indications

Chronic hepatitis B

Tenofovir disoproxil fumarate

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Chronic hepatitis B

Terizidone

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to cycloserine for

Multi-drug resistant Mycobacterium tuberculosis

Tetracycline

Section

Access group antibiotics
Oral > Solid: 250 mg (hydrochloride)

Indications

Bacterial infection of unspecified site

Tigecycline

Section

Reserve group antibiotics
Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

Other specified bacterial diseases

Tinidazole

Section

Antiamoebic and anti giardiasis medicines

Indications

Therapeutic equivalent to metronidazole for

Amoebiasis

Triclabendazole

Section

Antischistosomes and other antitrematode medicines
Oral > Solid > tablet: 250 mg (scored)

Indications

Paragonimiasis

Fascioliasis

Trimethoprim

Section

Access group antibiotics
Oral > Liquid: 50 mg per mL
Oral > Solid: 100 mg; 200 mg

Indications

First choice

Infectious cystitis

Valaciclovir

Section

Antiherpes medicines

Indications

Therapeutic equivalent to [aciclovir](#) for

Zoster

Therapeutic equivalent to [aciclovir](#) for

Varicella

Therapeutic equivalent to [aciclovir](#) for

Herpes simplex infections

Valganciclovir

Section

Other antivirals
Oral > Liquid: 50 mg per mL powder for oral solution
Oral > Solid > tablet: 450 mg

Indications

Cytomegaloviral retinitis

Vancomycin

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection

Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

First choice

Necrotising fasciitis

co-prescribed with ceftazidime

Endophthalmitis

co-prescribed with ceftriaxone

Endophthalmitis

Second choice

Neutropenia (high-risk)

Intestinal infections due to *Clostridioides difficile*

Other indications

Methicillin resistant *Staphylococcus aureus*

Voriconazole

Section

Antifungal medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection

Oral > Liquid: 40 mg per mL powder for oral liquid

Oral > Solid: 50 mg tablet; 200 mg tablet

Indications

Chronic pulmonary aspergillosis

Invasive aspergillosis

Zidovudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion

Oral > Liquid: 50 mg per 5 mL

Oral > Solid > tablet: 300 mg

Oral > Solid > capsule: 250 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified